Mirtazapine Relonchem

Mirtazapine, the active ingredient in Mirtazapine Relonchem, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral dosage form for oral use. It is prescribed to treat major depressive disorder in adult patients.

GNH USA supplies Mirtazapine Relonchem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across multiple regions. The product meets European Union pharmacopeial standards and is manufactured under rigorous international Good Manufacturing Practice guidelines.

Mirtazapine is a NaSSA antidepressant that acts on neurotransmitter pathways implicated in mood disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients. - Depression with insomnia: helps alleviate depressive symptoms while improving sleep quality. - Depression with loss of appetite: may increase appetite and promote weight gain as part of overall symptom management.

Mirtazapine may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects: - Drowsiness or sedation - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Hypersensitivity reactions including rash or angioedema - Emergence of suicidal thoughts, especially early in therapy - Hepatic dysfunction or jaundice

Before initiating therapy, clinicians should consider several safety measures.

- Monitor weight: watch for significant weight gain and adjust diet as needed. - Assess for suicidal ideation: especially during the first weeks of treatment. - Use caution in hepatic impairment: dose adjustments may be required. - Adjust dose in elderly patients: start low and titrate slowly. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture.

Mirtazapine can interact with other medicines; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis or serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, triptans): may precipitate serotonin syndrome. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - CNS depressants (alcohol, benzodiazepines): additive sedation. - Antihypertensive drugs: possible additive hypotensive effect. - Anticholinergic medications: may exacerbate dry mouth and constipation. - NSAIDs or anticoagulants: monitor for increased bleeding risk.